RT Journal Article SR Electronic T1 The Inhibitory Effect of 111In-DTPA0-Octreotide on Intrahepatic Tumor Growth After Partial Hepatectomy JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1681 OP 1687 VO 43 IS 12 A1 Gerrit D. Slooter A1 Arend G.J. Aalbers A1 Wouter A.P. Breeman A1 Coen A. Hiemstra A1 Richard L. Marquet A1 Eric P. Krenning A1 Casper H.J. van Eijck YR 2002 UL http://jnm.snmjournals.org/content/43/12/1681.abstract AB The aim of this animal study was to evaluate whether peptide receptor radionuclide therapy with 111In-diethylenetriaminepentaacetic acid (DTPA)0-octreotide was able to reduce tumor growth even under tumor growth-stimulating conditions induced by partial hepatectomy (PHx). Methods: Rats underwent 70% PHx or sham operation. The development of hepatic metastases was determined 21 d after direct injection of somatostatin receptor (SS-R)-positive or SS-R-negative tumor cells into the portal vein. Groups of 8 or 9 animals that underwent PHx or sham operation were treated with octreotide 50 μg/kg subcutaneously twice daily or with 370 MBq 111In-DTPA0-octreotide intravenously on days 1 and 8. Both treatments were compared with control treatment. Forty non-tumor-bearing rats were used to determine the influence of 111In-DTPA0-octreotide therapy on liver regeneration after PHx. Results: PHx induced an increase in tumor growth in all experiments (P < 0.01). Octreotide treatment did not influence tumor growth after PHx or sham operation. 111In-DTPA0-octreotide could effectively reduce tumor growth in the liver of SS-R-positive tumors also under conditions of increased tumor growth as generated by PHx (P < 0.01). 111In-DTPA0-octreotide was also effective on SS-R-negative tumors after PHx (P = 0.01) but not after sham operation. Furthermore, 111In-DTPA0-octreotide therapy did not influence liver regeneration or liver function after PHx. Conclusion: Peptide receptor radionuclide therapy with 111In-DTPA0-octreotide is effective in SS-R-positive tumors. During liver regeneration, the growth of SS-R-negative tumors is also reduced. This effect is not induced by impairment of liver regeneration or liver function. Radionuclide therapy could therefore be a promising treatment modality for patients with symptomatic liver metastases of neuroendocrine tumors in combination with liver resection.